- 著者
-
高野 浩一
森下 宗彦
山本 正彦
山県 香
高田 勝利
- 出版者
- The Japanese Respiratory Society
- 雑誌
- 日本胸部疾患学会雑誌 (ISSN:03011542)
- 巻号頁・発行日
- vol.15, no.11, pp.769-774, 1977-11-25 (Released:2010-02-23)
- 参考文献数
- 12
BCG-CWS was administered in 30 patients with primary lung cancer, and in most cases this was in conjunction with other therapeutic procedures such as irradiation, chemotherapy and/or surgery.Oil-attached BCG-CWS was prepared by homogenizing 4mg of BCG-CWS, two drops of mineral oil and 2ml of 0.2% Tween 80 saline.Two hundred μg of BCG-CWS was injected intradermally every week. In patients with carcinomatous pleuritis, 400μg of BCG-CWS was injected into the pleural cavity every week.Prolonged survival periods in advanced lung cancer cases treated with BCG-CWS was observed in comparison with historical controls. Most of the patients showed increased PPD skin reaction and increased in vitro PHA response after BCG-CWS administration.As adverse reactions, minimal skin ulceration was observed in 37% of the patients, and fever in 57% after repeated intradermal injection of BCG-CWS, none of which necessitated the interruption of immunotherapy. No serious side effects, however, have been observed during the BCG-CWS treatment.